Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma

References

• Swerdlow SH, Campo E, and Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: World Health Organization; 2017.
   Google Scholar
• Fukumura K, Kawazu M, Kojima S, et al. Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol. 2016 Jun;131(6):865–875.
   PubMed Web of Science ®Google Scholar
• Braggio E, Van Wier S, Ojha J, et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;21(17):3986–3994.
   PubMed Web of Science ®Google Scholar
• Vater I, Montesinos-Rongen M, Schlesner M, et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2015;29(3):677–685.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Roemer MG, and Stewart C, et al., Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 127(7): 869–881. 2016.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Holdhoff M, Nayak L, et al. Evolving treatments for primary central nervous system lymphoma. Am Soc Clin Oncol Educ Book. 2019;39(39):454–466.
   PubMedGoogle Scholar
• Khatab S, Spliet W, Woerdeman PA. Frameless image-guided stereotactic brain biopsies: emphasis on diagnostic yield. Acta Neurochir (Wien). 2014Aug;156(8):1441–1450. Epub 2014 Jun 5.
   PubMed Web of Science ®Google Scholar
• Kersten MJ, Evers LM, Dellemijn PL, et al. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood. 1996;87(5):1985–1989.
   PubMed Web of Science ®Google Scholar
• Smith JR, Braziel RM, Paoletti S, et al. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2003;101(3):815–821.
   PubMed Web of Science ®Google Scholar
• Caudie C, Bancel J, Dupont M, et al. CSF levels and diagnostic utility of cerebrospinal fluid beta 2-microglobulin. Ann Biol Clin (Paris). 2005;63(6):631–637.
   PubMed Web of Science ®Google Scholar
• Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008;26(1):96–105.
   PubMed Web of Science ®Google Scholar
• Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140–3146.
   PubMed Web of Science ®Google Scholar
• Sasayama T, Nakamizo S, Nishihara M, et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro-Oncol. 2012;14(3):368–380.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Wong VS, Kadoch C, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121(23):4740–4748.
   PubMed Web of Science ®Google Scholar
• Viaccoz A, Ducray F, Tholance Y, et al. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neuro Oncol. 2015;17(11):1497–1503.
   PubMed Web of Science ®Google Scholar
• Song Y, Zhang W, and Zhang L, et al., Cerebrospinal fluid IL-10 and IL-10/IL-6 as accurate diagnostic biomarkers for primary central nervous system large B-cell lymphoma. Sci Rep. 2016;6(1): 38671.
   PubMedGoogle Scholar
• Strehlow F, Bauer S, Martus P, et al. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. J Neuro-Oncol. 2016;129(1):165–171.
   PubMed Web of Science ®Google Scholar
• Nguyen-Them L, Costopoulos M, Tanguy ML, et al. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur J Cancer. 2016 Jul;61:69–76.
   PubMed Web of Science ®Google Scholar
• Thaler FS, Laurent SA, Huber M, et al. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma. Neuro Oncol. 2017 Nov 29;19(12):1618–1627.
   PubMed Web of Science ®Google Scholar
• Baraniskin A, Chomiak M, Ahle G, et al. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS. J Neurooncol. 2018 May;137(3):463–468.
   PubMed Web of Science ®Google Scholar
• Van Westrhenen A, Smidt LCA, Seute T, et al. Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review. Br J Haematol. 2018 Aug;182(3):384–403.
   PubMed Web of Science ®Google Scholar
• Mulazzani M, Huber M, Borchard S, et al. April and BAFF: novel biomarkers for central nervous system lymphoma. J Hematol Oncol. 2019 Oct 15;12(1):102.
   PubMed Web of Science ®Google Scholar
• Baraniskin A, Kuhnhenn J, Schlegel U, et al. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J NeuroOncol. 2012a;109(2):239–244.
   PubMed Web of Science ®Google Scholar
• Malzkorn B, Wolter M, Liesenberg F, et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol. 2010;20(3):539–550.
   PubMed Web of Science ®Google Scholar
• Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65(21):9628–9632.
   PubMed Web of Science ®Google Scholar
• Kim K, Chadalapaka G, Lee SO, et al. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene. 2012;31(8):1034–1044.
   PubMed Web of Science ®Google Scholar
• Wang L, Luo L, Gao Z, et al. The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis. Leuk Lymphoma. 2017 Oct;58(10):2452–2459.
   PubMed Web of Science ®Google Scholar
• Kimura A, Yoshikura N, Koumura A, et al. B-cell-activating factor belonging to the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (April) levels in cerebrospinal fluid of patients with meningoencephalitis. J Neurol Sci. 2015;352(1–2):79–83.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, and Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 May;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Kraan W, Horlings HM, van Keimpema M, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013 Sep 6;3(9):e139.
   PubMedGoogle Scholar
• King RL, Goodlad JR, and Calaminici M, et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch. 2020 May;476(5): 647–665.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011 Jun;11(6):426–437.
   PubMed Web of Science ®Google Scholar
• Bonzheim I, Giese S, Deuter C, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015 Jul 2;126(1):76–79.
   PubMed Web of Science ®Google Scholar
• Fontanilles M, Marguet F, É B, et al. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017 Jul 18;8(29):48157–48168.
   PubMed Web of Science ®Google Scholar
• Watanabe J, Natsumeda M, Okada M, et al., High detection rate of MYD88 mutations in cerebrospinal fluid from patients with CNS lymphomas. JCO Precis Oncol. 2019;3(3): 1–13.
   PubMedGoogle Scholar
• Ferreri AJM, Calimeri T, and Lopedote P, et al. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol. 2021 Feb 23;193(3):497–505.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, D’Sa S, Lunn MP, et al. Central nervous system involvement by Waldenstrom macroglobulinaemia (Bing‐Neel syndrome): a multi‐institutional retrospective study. Br J Haematol. 2016;172(5):709‐715.
   Web of Science ®Google Scholar
• Poulain S, Boyle EM, Roumier C, et al. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol. 2014;167(4):506‐513.
   PubMed Web of Science ®Google Scholar
• Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, et al. The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p. (L265P) detection in cerebrospinal fluid. Hematol Oncol. 2018 Apr;36(2):429–435.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Ferreri AJM, Giuffrè C, et al. MYD88 L265P mutation detection in the aqueous humor of patients with vitreoretinal lymphoma. Retina. 2019 Apr;39(4):679–684.
   PubMed Web of Science ®Google Scholar
• Hiemcke-Jiwa LS, Dam-van Loon NHT, Leguit RJ, et al. Potential diagnosis of vitreoretinal lymphoma by detection of MYD88 mutation in aqueous humor with ultrasensitive droplet digital polymerase chain reaction. JAMA Ophthalmol. 2018;136(10):1098.
   PubMed Web of Science ®Google Scholar
• Korfel A, Schlegel U, Herrlinger U, et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol. 2016;34(15):1757–1763.
   PubMedGoogle Scholar
• Kuhn JG, Chang SM, Wen PY, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007;13(24):7401–7406.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Sheen C, Hall J, et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood. 2008;112(5):2020–2023.
   PubMed Web of Science ®Google Scholar
• Grommes C, Pentsova E, Nolan C, et al. Phase II study of single agent buparlisib in recurrent/ refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Ann Oncol. 2016;27(Supplement 6):vi103–vi113.
   Google Scholar
• Beaufils F, Cmiljanovic N, Cmiljanovic V, et al. 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology. J Med Chem. 2017;60(17):7524–7538.
   PubMed Web of Science ®Google Scholar
• Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappa B in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717–721.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–119.
   PubMed Web of Science ®Google Scholar
• Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14(4):219–232.
   PubMed Web of Science ®Google Scholar
• Goldwirt L, Beccaria K, Ple A, et al. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol. 2018;81(4):783–789.
   PubMed Web of Science ®Google Scholar
• Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–1029.
   PubMed Web of Science ®Google Scholar
• Soussain C, Choquet S, and Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121–130.
   PubMed Web of Science ®Google Scholar
• Mathews Griner LA, Guha R, Shinn P, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014;111(6):2349–2354.
   PubMed Web of Science ®Google Scholar
• Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF kappa B. J Clin Invest. 2001;107(3):241–246.
   PubMed Web of Science ®Google Scholar
• Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019;133(5):436–445.
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–843.e5.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Melani C, Lakhotia R, et al. Phase 1 study of escalating doses of ibrutinib and temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDI-R) with isavuconazole for relapsed and refractory primary CNS lymphoma. Blood. 2020 November;136(Supplement 1):12–13. Abstract #2110
   Google Scholar
• Chen F, Pang D, Guo H, et al. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: a real-world experience of off-label ibrutinib use. Cancer Med. 2020 Nov;9(22):8676–8684.
   PubMed Web of Science ®Google Scholar
• Narita Y, Nagane M, and Mishima K, et al. Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2021 Jan 30;23(1):122–133.
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008 Jan;140(1):36–45.
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69(1–2):56–63.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595–1607.
   PubMed Web of Science ®Google Scholar
• Tun HW, Johnston PB, DeAngelis LM, et al. Phase I study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018;132(21):2240–2248.
   PubMed Web of Science ®Google Scholar
• Li Z, Qiu Y, Personett D, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013;8(8):e71754.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL. Biology of CNS lymphoma and the potential of novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017(1):556–564.
   PubMedGoogle Scholar
• Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454(7201):226–231.
   PubMed Web of Science ®Google Scholar
• Li S, Pal R, Monaghan SA, et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 2011;117(19):5157–5165.
   PubMed Web of Science ®Google Scholar
• Houillier C, Choquet S, Touitou V, et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology. 2015 Jan 20;84(3):325–326.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11(16):5984–5992.
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Chevrier M, and Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French oculo-cerebral lymphoma (LOC) network and the lymphoma study association (LYSA). Ann Oncol. 2019 Apr 1;30(4):621–628.
   PubMed Web of Science ®Google Scholar
• Muscal JA, Sun Y, Nuchtern JG, et al. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol. 2012 Apr;69(4):252–262.
   Web of Science ®Google Scholar
• Harjunpää A, Wiklund T, Collan J, et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma. 2001 Aug;42(4):731–738.
   PubMed Web of Science ®Google Scholar
• Vu K, Manni G, Hwang J, et al. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol. 2019 Jul;186(1):180–183.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Hwang J, and Mannis G, et al. Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL. Hematol Oncol. 2017;35:343–344.
   Google Scholar
• Qiu Y, Li Z, Pouzoulet F, et al. Immune checkpoint inhibition by antiPDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model. Br J Haematol. 2018;183(4):674–678.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017 Jun 8;129(23):3071–3073.
   PubMed Web of Science ®Google Scholar
• Gavrilenko AN, Volkov NP, Shmidt DI, et al. Nivolumab in primary CNS lymphoma and primary testicular lymphoma with CNS involvement: single center experience. Blood. 2020;136(Supplement 1):4.
   PubMedGoogle Scholar
• Furuse M, Nonoguchi N, Omura N, et al. Immunotherapy of nivolumab with dendritic cell vaccination is effective against intractable recurrent primary central nervous system lymphoma: a case report. Neurol Med Chir (Tokyo). 2017 Apr 15;57(4):191–197.
   PubMed Web of Science ®Google Scholar
• Chan TSY, Khong PL, Au-Yeung R, et al. Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma. Ann Hematol. 2019 Sep;98(9):2227–2230.
   PubMed Web of Science ®Google Scholar
• Terziev D, Hutter B, Klink B, et al. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma. Eur J Haematol. 2018 Jul;101(1):115–118.
   PubMed Web of Science ®Google Scholar
• Ambady P, Szidonya L, Firkins J, et al. Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. Leuk Lymphoma. 2019 Feb;60(2):515–518.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Abramson SJ, Gordon L, Lia Palomba M, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36(15_suppl):7505.
   Web of Science ®Google Scholar
• Abramson JS, McGree B, and Noyes S, et al., Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017;377(8): 783–784.
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019 Sep 12;134(11):860–866.
   PubMed Web of Science ®Google Scholar
• Novo M, Ruff MW, Skrabek PJ, et al. Axicabtagene ciloleucel chimeric antigen receptor t cell therapy in lymphoma with secondary central nervous system involvement. Mayo Clin Proc. 2019 Nov;94(11):2361–2364.
   PubMed Web of Science ®Google Scholar
• Tu S, Zhou X, Guo Z, et al. CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma. Front Oncol. 2019 Dec 4;9:1350.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Calimeri T, Conte GM, et al. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma. Blood. 2019;134(3):252–262.
   PubMed Web of Science ®Google Scholar